Development and validation of RSClin N plus tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer

被引：0
|
作者：
Pusztai, Lajos
Hoag, Jess R.
Albain, Kathy S.
Barlow, William E.
Stemmer, Salomon M.
Meisner, Allison
Hortobagyi, Gabriel N.
Shak, Steven
Hayes, Daniel F.
Rae, James M.
Baehner, Frederick
Sharma, Priyanka
Kalinsky, Kevin
机构：
[1] Yale Univ, Canc Ctr, New Haven, CT USA
[2] Exact Sci, Redwood City, CA USA
[3] Loyola Univ, Chicago Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL USA
[4] Canc Res & Biostat CRAB, Seattle, WA USA
[5] Rabin Med Ctr, Petah Tiqwa, Israel
[6] Fred Hutchinson Canc Ctr, Div Publ Hlth Sci, Seattle, WA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA
[8] Univ Michigan Hlth Syst, Comprehens Canc Ctr, Ann Arbor, MI USA
[9] Michigan Med, Ann Arbor, MI USA
[10] Univ Kansas, Canc Ctr, Westwood, KS USA
[11] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
508
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HEALTH OUTCOME GAINS AND COSTS OFFSET ASSOCIATED WITH EVEROLIMUS FOR THE TREATMENT OF HORMONE-RECEPTOR-POSITIVE (HR+) HER2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
    Taylor, M.
    Lewis, L.
    Vieira, J.
    Ricci, J. F.
    Chandiwana, D.
    Saletan, S.
    Sahmoud, T.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A427 - A427
  • [32] A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
    Li, Allen
    Naik, Arpana
    Johnson, Nathalie
    Goodyear, Shaun
    Johnson, Brett
    Park, Byung
    Corless, Christopher
    Gray, Joe
    Mills, Gordon
    Mitri, Zahi
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [33] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shohei Shikata
    Takeshi Murata
    Masayuki Yoshida
    Hiromi Hashiguchi
    Yukiko Yoshii
    Ayumi Ogawa
    Chikashi Watase
    Sho Shiino
    Hirokazu Sugino
    Kenjiro Jimbo
    Akiko Maeshima
    Eriko Iwamoto
    Shin Takayama
    Akihiko Suto
    [J]. Scientific Reports, 13
  • [34] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shikata, Shohei
    Murata, Takeshi
    Yoshida, Masayuki
    Hashiguchi, Hiromi
    Yoshii, Yukiko
    Ogawa, Ayumi
    Watase, Chikashi
    Shiino, Sho
    Sugino, Hirokazu
    Jimbo, Kenjiro
    Maeshima, Akiko
    Iwamoto, Eriko
    Takayama, Shin
    Suto, Akihiko
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [35] COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) EARLY BREAST CANCER
    Tejerina-Peces, Julia
    Amann-Arevalo, Marta
    Ballestin, Pablo
    Gonzalez-Diez, Beatriz
    Paz-Cabezas, Mateo
    Pascual, Alejandro
    de Luna, Alicia
    Garcia-Barberan, Vanesa
    Lopez de Sa, Alfonso
    Garcia-Saenz, Jose Angel
    Moreno, Fernando
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [36] Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer
    Du, Lili
    Yau, Christina
    Brown-Swigart, Lamorna
    Gould, Rebekah
    Hirst, Gillian L.
    van der Noordaa, Marieke
    Bedrosian, Isabelle
    Layman, Rachel M.
    Valero, Vicente
    Van't Veer, Laura
    Esserman, Laura
    Symmans, W. Fraser
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [37] Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial
    Braso-Maristany, Fara
    Falato, Claudette
    Martinez-Saez, Olga
    Cejalvo, Juan Miguel
    Margeli, Mireia
    Tolosa, Pablo
    Bofill, Francisco Javier Salvador
    Cruz, Josefina
    Gonzalez-Farre, Blanca
    Sanfeliu, Esther
    Arumi, Miriam
    Villacampa, Guillermo
    Ciruelos, Eva
    Espinosa-Bravo, Martin
    Izarzuzaga, Yann
    Galvan, Patricia
    Matito, Judit
    Pernas, Sonia
    Santhanagopal, Anu
    Esker, Stephen
    Patel, Parul
    Fan, Pang-Dian
    Ferrero-Cafiero, Juan Manuel
    Vivancos, Ana
    Pascual, Tomas
    Prat, Aleix
    Oliveira, Mafalda
    Ferrero-Cafiero, Juan Manuel
    Vivancos, Ana
    Pascual, Tomas
    Prat, Aleix
    Oliveira, Mafalda
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [38] Abemaciclib plus endocrine therapy for hormone receptor- positive, HER2-negative, node-positive, high-risk, early breast cancer
    Nozawa, Kazuki
    Sawaki, Masataka
    Iwata, Hiroji
    [J]. LANCET ONCOLOGY, 2023, 24 (03): : E103 - E103
  • [39] Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer
    Choi, Woo Jung
    Sim, Hayan
    Kim, Hee Jeong
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    Kim, Hak Hee
    [J]. ACTA RADIOLOGICA, 2021, 62 (12) : 1592 - 1600
  • [40] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Andrahennadi, Samitha
    Sami, Amer
    Manna, Mita
    Pauls, Mehrnoosh
    Ahmed, Shahid
    [J]. CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822
12345